AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16099293 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative radiotherapy (60 Gy conventional irradiation delivered over 6 weeks)
Number of subjects: 1005
Study 16099293 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation group
Number of subjects: 1005
Study 16099293 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see group
Number of subjects: 1005
Study 11374333 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine
Number of subjects: 26
Study 11374333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9803985 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral tablet dose of 20 mg temocapril hydrochloride
Number of subjects: 36
Study 9803985 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven once daily oral tablet doses of 20 mg temocapril hydrochloride
Number of subjects: 36
Study 8056004 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 145
Study 8056004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 2973597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-vancomycin (group A)
Number of subjects: 66
Study 2973597 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin-vancomycin-amikacin (group B)
Number of subjects: 66
Study 31315733 — intervention group
Group type: EXPERIMENTAL
Intervention: NTI-guided sedation assessment
Number of subjects: 87
Study 31315733 — intervention group
Group type: COMPARATOR
Intervention: RASS-guided sedation assessment
Number of subjects: 87
Study 28991614 — intervention group
Group type: EXPERIMENTAL
Intervention: In-the-bag IOL with anterior vitrectomy (Group 1)
Number of subjects: 61
Study 28991614 — intervention group
Group type: COMPARATOR
Intervention: Optic capture of IOL without anterior vitrectomy (Group 2)
Number of subjects: 61
Study 25490706 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 3255
Study 25490706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg + Fluticasone furoate (FF) 50 μg
Number of subjects: 3255
Study 25490706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg + Fluticasone furoate (FF) 100 μg
Number of subjects: 3255
Study 25490706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg + Fluticasone furoate (FF) 200 μg
Number of subjects: 3255
Study 23337228 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 100
Study 23337228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23337228 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril class 1
Number of subjects: 100
Study 23337228 — intervention group
Group type: COMPARATOR
Intervention: Placebo class 1
Number of subjects: 100
Study 23337228 — intervention group
Group type: COMPARATOR
Intervention: Placebo/enalapril class 1
Number of subjects: 100
Study 23337228 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo/enalapril class 2
Number of subjects: 100
Study 20352312 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMSCIS program with emergency information forms (EIF)
Number of subjects: 170
Study 20352312 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMSCIS program
Number of subjects: 170
Study 20352312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MEMSCIS program)
Number of subjects: 170
Study 19846281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg single dose)
Number of subjects: 12
Study 19846281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16982058 — intervention group
Group type: EXPERIMENTAL
Intervention: BM‐MNC sorted on a blood cell separator
Number of subjects: 12
Study 16982058 — intervention group
Group type: COMPARATOR
Intervention: BM‐MNC isolated by density gradient on Ficoll‐Hypaque
Number of subjects: 12
Study 15016255 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information provided prior to treatment
Number of subjects: 56
Study 15016255 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no written information)
Number of subjects: 56
Study 11256458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 9020437 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellectomy with advancement of the vastus medialis obliquus (group B)
Number of subjects: 28
Study 9020437 — intervention group
Group type: COMPARATOR
Intervention: Simple patellectomy (group A)
Number of subjects: 28
Study 7932194 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day lovastatin
Number of subjects: 9
Study 7932194 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day lovastatin
Number of subjects: 9
Study 7932194 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day lovastatin
Number of subjects: 9
Study 7932194 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/day lovastatin (baseline)
Number of subjects: 9
Study 31980416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-Axis Rotational Coronary Angiography (DARCA)
Number of subjects: 503
Study 29369893 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive insulation
Number of subjects: 292
Study 29369893 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 292
Study 29369893 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature (19°, 21°, or 23°C)
Number of subjects: 292
Study 27175685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 μg/kg/hour continuous infusion)
Number of subjects: 50
Study 27175685 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 50
Study 24662296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use complementary food (RUF)
Number of subjects: 248
Study 24662296 — intervention group
Group type: COMPARATOR
Intervention: Whole milk powder
Number of subjects: 248
Study 24662296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (RUF and milk powder)
Number of subjects: 248
Study 23206453 — intervention group
Group type: EXPERIMENTAL
Intervention: Di Huang Yin Zi (DHYZ)
Number of subjects: 60
Study 23206453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20187094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemoradiation with 4x150 mg/m(2) cisplatin administered in the tumor-feeding artery on Days 1, 8, 15, 22, followed by sodium thiosulfate and 70 Gy in 35 daily fractions.
Number of subjects: 239
Study 20187094 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemoradiation with 3x100 mg/m(2) cisplatin infusion on Days 1, 22, 43 and 70 Gy in 35 daily fractions.
Number of subjects: 239
Study 20187094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemoradiation
Number of subjects: 239
Study 20187094 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemoradiation
Number of subjects: 239
Study 18156614 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 1181
Study 18156614 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1181
Study 18156614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 1181
Study 17042146 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 23
Study 17042146 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 23
Study 17042146 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 180 microg
Number of subjects: 23
Study 17042146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 14616279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation (ES) of the pelvic floor
Number of subjects: 35
Study 14616279 — intervention group
Group type: COMPARATOR
Intervention: Kegel exercise (KE) program
Number of subjects: 35
Study 11042755 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care (n = 446)
Number of subjects: 887
Study 11042755 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 441)
Number of subjects: 887
Study 8970752 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-point I-GERQ GERD score based on 11 items on the questionnaire
Number of subjects: 135
Study 8970752 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-point I-GERQ GERD score
Number of subjects: 135
Study 8970752 — intervention group
Group type: COMPARATOR
Intervention: Normal infants
Number of subjects: 135
Study 8970752 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental smoke exposure
Number of subjects: 135
Study 1433121 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise programme
Number of subjects: 0
Study 1433121 — intervention group
Group type: COMPARATOR
Intervention: Low intensity exercise
Number of subjects: 0
Study 3919531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus glibenclamide, 5 mg twice daily
Number of subjects: 13
Study 3919531 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus placebo
Number of subjects: 13
Study 31174713 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label injectable hydromorphone
Number of subjects: 108
Study 31174713 — intervention group
Group type: COMPARATOR
Intervention: Double-blind injectable opioid agonist treatment (iOAT)
Number of subjects: 108
Study 31174713 — intervention group
Group type: COMPARATOR
Intervention: Open-label injectable hydromorphone vs Double-blind iOAT
Number of subjects: 108
Study 31174713 — intervention group
Group type: COMPARATOR
Intervention: Open-label injectable hydromorphone and Double-blind iOAT
Number of subjects: 108
Study 29947355 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality goggles
Number of subjects: 97
Study 29947355 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 97
Study 26884557 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA arm (treatment allocation based on Comprehensive Geriatric Assessment)
Number of subjects: 494
Study 26884557 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (chemotherapy allocation based on performance status and age)
Number of subjects: 494
Study 26884557 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA arm
Number of subjects: 494
Study 26884557 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 494
Study 25182272 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical repellents
Number of subjects: 940
Study 25182272 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 940
Study 22268183 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. iohexol
Number of subjects: 389
Study 22268183 — intervention group
Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 389
Study 22268183 — intervention group
Group type: COMPARATOR
Intervention: Comparison of iohexol and iopamidol
Number of subjects: 389
Study 22268183 — intervention group
Group type: COMPARATOR
Intervention: Contrast-induced nephropathy rates
Number of subjects: 389
Study 19625343 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (70 mg/m²) and Docetaxel (25 mg/m²) administered on days 1 and 8 of each 3-week cycle
Number of subjects: 70
Study 19625343 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and Docetaxel
Number of subjects: 70
Study 18172223 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 90
Study 18172223 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/day
Number of subjects: 90
Study 16353468 — intervention group
Group type: EXPERIMENTAL
Intervention: Centric occlusion stabilization oral appliance
Number of subjects: 22
Study 16353468 — intervention group
Group type: COMPARATOR
Intervention: Non-appliance wearing days
Number of subjects: 22
Study 11927703 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 1 week
Number of subjects: 176
Study 11927703 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 2 weeks
Number of subjects: 176
Study 11927703 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 4 weeks
Number of subjects: 176
Study 9809926 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (10 mg twice a day)
Number of subjects: 24
Study 9809926 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol (10 mg twice a day)
Number of subjects: 24
Study 9809926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8561267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (total dose = 550 mg or 9.6 mg/kg)
Number of subjects: 50
Study 8561267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (total dose = 8.8 mg/kg)
Number of subjects: 50
Study 2692838 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (LA.P), 160 mg once-daily
Number of subjects: 55
Study 2692838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 322152 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (2 and 10 mg)
Number of subjects: 12
Study 322152 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 31843246 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stockings for 3 weeks
Number of subjects: 135
Study 31843246 — intervention group
Group type: COMPARATOR
Intervention: Control (no elastic compression)
Number of subjects: 135
Study 31145281 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 SMS per week offering advice, motivation, and information about medication adherence, physical activity, dietary measures, and smoking cessation (if appropriate)
Number of subjects: 160
Study 31145281 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 SMS per week
Number of subjects: 160
Study 31145281 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 160
Study 27008585 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (cycle ergometer at 60% HR max for 40 minutes)
Number of subjects: 50
Study 27008585 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (3 upper and 3 lower extremity movements at 60% of 1-RM, 60 minutes)
Number of subjects: 50
Study 27008585 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent exercise (combination of aerobic and resistance protocols, 60 minutes)
Number of subjects: 50
Study 27008585 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal shuttle run test (4 trials of 40-meter MSRT, 30 minutes)
Number of subjects: 50
Study 27008585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 50
Study 26480549 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) assisted with surface electromyography (sEMG)
Number of subjects: 60
Study 26480549 — intervention group
Group type: COMPARATOR
Intervention: Conventional electro-acupuncture (EA)
Number of subjects: 60
Study 23637279 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchange mask (HME)
Number of subjects: 53
Study 23637279 — intervention group
Group type: COMPARATOR
Intervention: Placebo mask (PL)
Number of subjects: 53
Study 23637279 — intervention group
Group type: COMPARATOR
Intervention: No mask (NM)
Number of subjects: 53
Study 21288211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg pre-incision
Number of subjects: 175
Study 21288211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg pre-incision
Number of subjects: 175
Study 21288211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg post-incision
Number of subjects: 175
Study 21288211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg post-incision
Number of subjects: 175
Study 21288211 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 600 mg pre-incision
Number of subjects: 175
Study 21288211 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 600 mg post-incision
Number of subjects: 175
Study 21288211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 18626764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (15 sessions)
Number of subjects: 467
Study 18626764 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 467
Study 16424410 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol, 24 microg bid
Number of subjects: 2085
Study 16424410 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol, 12 microg bid plus on-demand
Number of subjects: 2085
Study 16424410 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol, 12 microg bid
Number of subjects: 2085
Study 16424410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2085
Study 16424410 — intervention group
Group type: EXPERIMENTAL
Intervention: All formoterol treatment regimens
Number of subjects: 2085
Study 12819323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (ACE inhibitor)
Number of subjects: 650
Study 12819323 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 650
Study 12819323 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 650
Study 12819323 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended anti-hypertensive therapy
Number of subjects: 650
Study 10858404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 79
Study 10858404 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 79
Study 9168080 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 100
Study 9168080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9168080 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (CABG)
Number of subjects: 100
Study 8247239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone in high but rapidly decreasing doses
Number of subjects: 43
Study 8247239 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 43
Study 2935349 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (1, 1, 2, and 4 mg)
Number of subjects: 24
Study 2935349 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (1.25, 1.25, 2.5, and 5.0 mg)
Number of subjects: 24
Study 2935349 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 2935349 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 24
Study 2935349 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol vs Celiprolol
Number of subjects: 24
Study 31702643 — intervention group
Group type: EXPERIMENTAL
Intervention: HT080 (500 mg) twice a day for 12 weeks
Number of subjects: 100
Study 31702643 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice a day for 12 weeks
Number of subjects: 100
Study 28333516 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-office collaborative care (DOCC)
Number of subjects: 321
Study 28333516 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 321
Study 25308300 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI=100% (complete revascularisation)
Number of subjects: 2618
Study 25308300 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI=50-99%
Number of subjects: 2618
Study 25308300 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI<50%
Number of subjects: 2618
Study 25308300 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI cut-off <80%
Number of subjects: 2618
Study 25308300 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI as an independent predictor of one-year mortality
Number of subjects: 2618
Study 25308300 — intervention group
Group type: COMPARATOR
Intervention: rSS compared to SRI
Number of subjects: 2618
Study 23192600 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 107
Study 23192600 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Disturbances factor of PSQI
Number of subjects: 107
Study 23192600 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married or partnered
Number of subjects: 107
Study 23192600 — intervention group
Group type: COMPARATOR
Intervention: Age, education, gender, and daytime sleepiness
Number of subjects: 107
Study 21311402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 1171
Study 21311402 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (open discectomy)
Number of subjects: 1171
Study 18648238 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 60
Study 18648238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 60
Study 18648238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17164728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (10 mg loading dose followed by 3 mg/m²/day, target levels 10-15 ng/mL for 6 months, then 5-10 ng/mL thereafter)
Number of subjects: 40
Study 17164728 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (4 to 8 mg/kg/day, target levels 150-300 ng/mL for 6 months, then 100-200 ng/mL thereafter)
Number of subjects: 40
Study 12626991 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygrolife HME
Number of subjects: 0
Study 12626991 — intervention group
Group type: EXPERIMENTAL
Intervention: EdithFlex HME
Number of subjects: 0
Study 12626991 — intervention group
Group type: COMPARATOR
Intervention: Both HMEs
Number of subjects: 0
Study 11740876 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pump
Number of subjects: 28
Study 11740876 — intervention group
Group type: COMPARATOR
Intervention: Manual expression
Number of subjects: 28
Study 11740876 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pump (at home)
Number of subjects: 28
Study 11740876 — intervention group
Group type: COMPARATOR
Intervention: Manual expression (at home)
Number of subjects: 28
Study 11740876 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast pump (in hospital)
Number of subjects: 28
Study 11740876 — intervention group
Group type: COMPARATOR
Intervention: Manual expression (in hospital)
Number of subjects: 28
Study 9407377 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV, Invirase) treatment
Number of subjects: 33